Celltrion Pharm, Inc.

KOSDAQ 068760.KQ

Celltrion Pharm, Inc. Price to Book Ratio (P/B) on January 14, 2025: 5.68

Celltrion Pharm, Inc. Price to Book Ratio (P/B) is 5.68 on January 14, 2025, a -50.34% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Celltrion Pharm, Inc. 52-week high Price to Book Ratio (P/B) is 8,184.56 on December 20, 2024, which is 144,087.33% above the current Price to Book Ratio (P/B).
Celltrion Pharm, Inc. 52-week low Price to Book Ratio (P/B) is 4.94 on December 09, 2024, which is -12.98% below the current Price to Book Ratio (P/B).
Celltrion Pharm, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 42.23.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

KOSDAQ: 068760.KQ

Celltrion Pharm, Inc.

CEO	Jung-su Seo
IPO Date	Feb. 3, 2006
Location	South Korea
Headquarters	82, 2sandan-ro
Employees	888
Sector	Health Care
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea.

Key trends

Past 5 years